258 related articles for article (PubMed ID: 22726118)
1. Potential role of TRAIL in the management of autoimmune diabetes mellitus.
Bernardi S; Norcio A; Toffoli B; Zauli G; Secchiero P
Curr Pharm Des; 2012; 18(35):5759-65. PubMed ID: 22726118
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
[TBL] [Abstract][Full Text] [Related]
3. Bioengineering strategies for inducing tolerance in autoimmune diabetes.
Baekkeskov S; Hubbell JA; Phelps EA
Adv Drug Deliv Rev; 2017 May; 114():256-265. PubMed ID: 28625830
[TBL] [Abstract][Full Text] [Related]
4. Original hypothesis: Extracorporeal shockwaves as a homeostatic autoimmune restorative treatment (HART) for Type 1 diabetes mellitus.
Craig K; d'Agostino C; Poratt D; Walker M
Med Hypotheses; 2014 Sep; 83(3):250-3. PubMed ID: 24947195
[TBL] [Abstract][Full Text] [Related]
5. Comparative Pathogenesis of Autoimmune Diabetes in Humans, NOD Mice, and Canines: Has a Valuable Animal Model of Type 1 Diabetes Been Overlooked?
O'Kell AL; Wasserfall C; Catchpole B; Davison LJ; Hess RS; Kushner JA; Atkinson MA
Diabetes; 2017 Jun; 66(6):1443-1452. PubMed ID: 28533295
[TBL] [Abstract][Full Text] [Related]
6. Targeting autoimmune diabetes with gene therapy.
Giannoukakis N; Rudert WA; Robbins PD; Trucco M
Diabetes; 1999 Nov; 48(11):2107-21. PubMed ID: 10535443
[TBL] [Abstract][Full Text] [Related]
7. Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.
Barcala Tabarrozzi AE; Castro CN; Dewey RA; Sogayar MC; Labriola L; Perone MJ
Clin Exp Immunol; 2013 Feb; 171(2):135-46. PubMed ID: 23286940
[TBL] [Abstract][Full Text] [Related]
8. Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough.
Ablamunits V; Sherry NA; Kushner JA; Herold KC
Ann N Y Acad Sci; 2007 Apr; 1103():19-32. PubMed ID: 17376841
[TBL] [Abstract][Full Text] [Related]
9. LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus.
Cobo-Vuilleumier N; Lorenzo PI; Rodríguez NG; Herrera Gómez IG; Fuente-Martin E; López-Noriega L; Mellado-Gil JM; Romero-Zerbo SY; Baquié M; Lachaud CC; Stifter K; Perdomo G; Bugliani M; De Tata V; Bosco D; Parnaud G; Pozo D; Hmadcha A; Florido JP; Toscano MG; de Haan P; Schoonjans K; Sánchez Palazón L; Marchetti P; Schirmbeck R; Martín-Montalvo A; Meda P; Soria B; Bermúdez-Silva FJ; St-Onge L; Gauthier BR
Nat Commun; 2018 Apr; 9(1):1488. PubMed ID: 29662071
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapies for type 1 diabetes mellitus.
Pozzilli P; Maddaloni E; Buzzetti R
Nat Rev Endocrinol; 2015 May; 11(5):289-97. PubMed ID: 25688000
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Popovic DS; Stokic E; Popovic SL
Curr Pharm Des; 2015; 21(36):5292-8. PubMed ID: 26438316
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats.
Dirice E; Sanlioglu AD; Kahraman S; Ozturk S; Balci MK; Omer A; Griffith TS; Sanlioglu S
Hum Gene Ther; 2009 Oct; 20(10):1177-89. PubMed ID: 19572802
[TBL] [Abstract][Full Text] [Related]
13. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes.
Eizirik DL; Colli ML; Ortis F
Nat Rev Endocrinol; 2009 Apr; 5(4):219-26. PubMed ID: 19352320
[TBL] [Abstract][Full Text] [Related]
14. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts.
Koulmanda M; Budo E; Bonner-Weir S; Qipo A; Putheti P; Degauque N; Shi H; Fan Z; Flier JS; Auchincloss H; Zheng XX; Strom TB
Proc Natl Acad Sci U S A; 2007 Aug; 104(32):13074-9. PubMed ID: 17670937
[TBL] [Abstract][Full Text] [Related]
15. Persistence of residual beta cells and islet autoimmunity during increasing duration of diabetes in NOD mice and experimental approaches toward reversing new-onset disease with bioactive peptides.
Reddy S; Cheung CC; Chai RC; Rodrigues JA
Ann N Y Acad Sci; 2008 Dec; 1150():171-6. PubMed ID: 19120289
[TBL] [Abstract][Full Text] [Related]
16. Prevention versus intervention of type 1 diabetes.
Brooks-Worrell B; Palmer JP
Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.
Yang Z; Chen M; Carter JD; Nunemaker CS; Garmey JC; Kimble SD; Nadler JL
Biochem Biophys Res Commun; 2006 Jun; 344(3):1017-22. PubMed ID: 16643856
[TBL] [Abstract][Full Text] [Related]
18. Type 1 diabetes mellitus.
Katsarou A; Gudbjörnsdottir S; Rawshani A; Dabelea D; Bonifacio E; Anderson BJ; Jacobsen LM; Schatz DA; Lernmark Å
Nat Rev Dis Primers; 2017 Mar; 3():17016. PubMed ID: 28358037
[TBL] [Abstract][Full Text] [Related]
19. New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.
Cernea S; Pozzilli P
Diabet Med; 2008 Nov; 25(11):1259-67. PubMed ID: 19046214
[TBL] [Abstract][Full Text] [Related]
20. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes.
Lamhamedi-Cherradi SE; Zheng S; Tisch RM; Chen YH
Diabetes; 2003 Sep; 52(9):2274-8. PubMed ID: 12941766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
